Abel Hall, LLC Ocugen, Inc. Call Options Transaction History
Abel Hall, LLC
- $216 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OCGN
# of Institutions
109Shares Held
62.8MCall Options Held
200KPut Options Held
151K-
Black Rock Inc. New York, NY17.9MShares$18.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.8MShares$15.2 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA4.15MShares$4.28 Million0.17% of portfolio
-
Geode Capital Management, LLC Boston, MA3.49MShares$3.59 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X01.73MShares$1.78 Million0.12% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $223M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...